Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 143
Filter
1.
Am J Prev Med ; 55(5 Suppl 1): S82-S87, 2018 11.
Article in English | MEDLINE | ID: mdl-30670205

ABSTRACT

INTRODUCTION: Although adolescence can be a difficult developmental period for all children, negative environmental forces make this period particularly risky for many inner-city black males. As part of the Center for Healthy African American Men through Partnerships, this project is utilizing community-based participatory concepts to design and implement programs to address risk-taking behaviors among middle school black males. METHODS: In 2014, parents of black males between the ages of 11 and 14years were recruited from an urban middle school to participate in focus group discussions. Letters were provided to the school to be mailed to parents inviting them to participate in discussion groups. Four focus groups were conducted. Data analyses were conducted fall 2014. RESULTS: Twenty-one parents participated. The major issue affecting the well-being and future success of young black males reported by parents was the lack of social support. Other areas of concern included negative peer pressure, bullying, violence, and lack of opportunities. Across groups, parents identified the lack of male parental presence in households and the subsequent perceived need by the young males to assume leadership roles, anger among the young males, and the lack of licensed counselors to address mental health issues as barriers to success and well-being. Parents emphasized the needs of the individual, family, and community for social support, positive role models, self-esteem, and respect. CONCLUSIONS: The present data can inform prevention programs designed to reduce disparities, such as educational underachievement, exposure to violence, and premature mortality experienced by black males. SUPPLEMENT INFORMATION: This article is part of a supplement entitled African American Men's Health: Research, Practice, and Policy Implications, which is sponsored by the National Institutes of Health.


Subject(s)
Adolescent Behavior , Black or African American/psychology , Focus Groups , Needs Assessment , Parents , Adolescent , Adult , Child , Community Participation , Humans , Male , Schools , Social Behavior , Social Determinants of Health , Social Support , Socioeconomic Factors , Urban Population
2.
AJNR Am J Neuroradiol ; 37(11): 1983-1991, 2016 Nov.
Article in English | MEDLINE | ID: mdl-27282864

ABSTRACT

BACKGROUND AND PURPOSE: Mild traumatic brain injury results in a heterogeneous constellation of deficits and symptoms that persist in a subset of patients. This prospective longitudinal study identifies early diffusion tensor imaging biomarkers of mild traumatic brain injury that significantly relate to outcomes at 1 year following injury. MATERIALS AND METHODS: DTI was performed on 39 subjects with mild traumatic brain injury within 16 days of injury and 40 controls; 26 subjects with mild traumatic brain injury returned for follow-up at 1 year. We identified subject-specific regions of abnormally high and low fractional anisotropy and calculated mean fractional anisotropy, axial diffusivity, radial diffusivity, and mean diffusivity across all white matter voxels brain-wide and each of several white matter regions. Assessment of cognitive performance and symptom burden was performed at 1 year. RESULTS: Significant associations of brain-wide DTI measures and outcomes included the following: mean radial diffusivity and mean diffusivity with memory; and mean fractional anisotropy, radial diffusivity, and mean diffusivity with health-related quality of life. Significant differences in outcomes were found between subjects with and without abnormally high fractional anisotropy for the following white matter regions and outcome measures: left frontal lobe and left temporal lobe with attention at 1 year, left and right cerebelli with somatic postconcussion symptoms at 1 year, and right thalamus with emotional postconcussion symptoms at 1 year. CONCLUSIONS: Individualized assessment of DTI abnormalities significantly relates to long-term outcomes in mild traumatic brain injury. Abnormally high fractional anisotropy is significantly associated with better outcomes and might represent an imaging correlate of postinjury compensatory processes.

3.
Br J Pharmacol ; 154(5): 1104-15, 2008 Jul.
Article in English | MEDLINE | ID: mdl-18454168

ABSTRACT

BACKGROUND AND PURPOSE: M1 muscarinic ACh receptors (mAChRs) represent an attractive drug target for the treatment of cognitive deficits associated with diseases such as Alzheimer's disease and schizophrenia. However, the discovery of subtype-selective mAChR agonists has been hampered by the high degree of conservation of the orthosteric ACh-binding site among mAChR subtypes. The advent of functional screening assays has enabled the identification of agonists such as AC-42 (4-n-butyl-1-[4-(2-methylphenyl)-4-oxo-1-butyl]-piperidine), which bind to an allosteric site and selectively activate the M(1) mAChR subtype. However, studies with this compound have been limited to recombinantly expressed mAChRs. EXPERIMENTAL APPROACH: In this study, we have compared the pharmacological profile of AC-42 and a close structural analogue, 77-LH-28-1 (1-[3-(4-butyl-1-piperidinyl)propyl]-3,4-dihydro-2(1H)-quinolinone) at human recombinant, and rat native, mAChRs by calcium mobilization, inositol phosphate accumulation and both in vitro and in vivo electrophysiology. KEY RESULTS: Calcium mobilization and inositol phosphate accumulation assays revealed that both AC-42 and 77-LH-28-1 display high selectivity to activate the M1 mAChR over other mAChR subtypes. Furthermore, 77-LH-28-1, but not AC-42, acted as an agonist at rat hippocampal M1 receptors, as demonstrated by its ability to increase cell firing and initiate gamma frequency network oscillations. Finally, 77-LH-28-1 stimulated cell firing in the rat hippocampus in vivo following subcutaneous administration. CONCLUSIONS AND IMPLICATIONS: These data suggest that 77-LH-28-1 is a potent, selective, bioavailable and brain-penetrant agonist at the M1 mAChR and therefore that it represents a better tool than AC-42, with which to study the pharmacology of the M1 mAChR.


Subject(s)
Hippocampus/drug effects , Muscarinic Agonists/pharmacology , Piperidines/pharmacology , Quinolones/pharmacology , Receptors, Muscarinic/drug effects , Action Potentials , Animals , CHO Cells , Calcium Signaling/drug effects , Cricetinae , Cricetulus , Dose-Response Relationship, Drug , Hippocampus/metabolism , Humans , Injections, Intraperitoneal , Injections, Subcutaneous , Inositol Phosphates/metabolism , Muscarinic Agonists/administration & dosage , Muscarinic Agonists/pharmacokinetics , Patch-Clamp Techniques , Permeability , Piperidines/administration & dosage , Piperidines/pharmacokinetics , Quinolones/administration & dosage , Quinolones/pharmacokinetics , Rats , Rats, Sprague-Dawley , Receptor, Muscarinic M1 , Receptors, Muscarinic/genetics , Receptors, Muscarinic/metabolism , Recombinant Proteins/agonists , Time Factors , Transfection
4.
Cancer Gene Ther ; 15(1): 1-8, 2008 Jan.
Article in English | MEDLINE | ID: mdl-17828282

ABSTRACT

Steady-state protein levels are determined by the balance between protein synthesis and degradation. Protein half-lives are determined primarily by degradation, and the major degradation pathways involve either lysosomal destruction or an ATP-dependent process involving ubiquitination to target proteins to the proteosome. Studies have shown that multiple tumor-suppressor proteins are ubiquitinated and degraded by the 26S proteasome. In the present study, we investigated whether the tumor suppressor/cytokine melanoma differentiation-associated gene-7/interleukin-24 gene (MDA-7/IL-24) protein is ubiquitinated and its degradation controlled by the proteasome. Treatment of ovarian (2008) and lung (H1299) tumor cells with adenoviral delivery of mda-7 (Ad-mda7) or Ad-mda7 plus the proteosome inhibitor MG132 showed that MDA-7 protein expression was dependent upon proteosome activity. Western blot and immunoprecipitation analyses verified that the MDA-7 protein was ubiquitinated and that ubiquitinated-MDA-7 levels were increased in MG132-treated cells. These results were confirmed using small interfering RNA (siRNA)-mediated knockdown of ubiquitin. Furthermore, ubiquitinated MDA-7 protein was degraded by the 26S proteasome, as MDA-7 accumulation was observed only when cells were treated with MG132 but not with lysosome or protease inhibitors. Inhibition of the catalytic beta-5 subunit of the 20S proteasome using siRNA resulted in MDA-7 protein accumulation. Finally, treatment of tumor cells with Ad-mda7 plus the proteasome inhibitor bortezomib resulted in increased tumor cell killing. Our results show that MDA-7/IL-24 is ubiquitinated and degraded by the 26S proteasome. Furthermore, inhibition of MDA-7 degradation results in enhanced tumor killing, identifying a novel anticancer strategy.


Subject(s)
Interleukins/biosynthesis , Lung Neoplasms/metabolism , Ovarian Neoplasms/metabolism , Proteasome Endopeptidase Complex/metabolism , Tumor Suppressor Proteins/biosynthesis , Ubiquitin/metabolism , Ubiquitination , Adenoviridae , Boronic Acids/pharmacology , Bortezomib , Catalytic Domain/genetics , Cell Line, Tumor , Female , Genetic Therapy , Humans , Interleukins/genetics , Lung Neoplasms/genetics , Lung Neoplasms/therapy , Lysosomes/genetics , Lysosomes/metabolism , Ovarian Neoplasms/genetics , Ovarian Neoplasms/therapy , Protease Inhibitors/pharmacology , Proteasome Endopeptidase Complex/genetics , Proteasome Inhibitors , Pyrazines/pharmacology , RNA, Small Interfering/biosynthesis , RNA, Small Interfering/genetics , Tumor Suppressor Proteins/genetics , Ubiquitin/antagonists & inhibitors , Ubiquitin/genetics , Ubiquitination/drug effects , Ubiquitination/genetics
5.
Gene Ther ; 10(23): 1961-9, 2003 Nov.
Article in English | MEDLINE | ID: mdl-14528320

ABSTRACT

The tumor-suppressor gene PTEN encodes a multifunctional phosphatase that is mutated in a variety of human cancers. PTEN inhibits the phosphatidylinositol 3-kinase pathway and downstream functions, including activation of Akt/protein kinase B (PKB), cell survival, and cell proliferation in tumor cells carrying mutant- or deletion-type PTEN. In such tumor cells, enforced expression of PTEN decreases cell proliferation through cell-cycle arrest at G1 phase accompanied, in some cases, by induction of apoptosis. More recently, the tumor-suppressive effect of PTEN has been reported in ovarian and thyroid tumors that are wild type for PTEN. In the present study, we examined the tumor-suppressive effect of PTEN in human colorectal cancer cells that are wild type for PTEN. Adenoviral-mediated transfer of PTEN (Ad-PTEN) suppressed cell growth and induced apoptosis significantly in colorectal cancer cells (DLD-1, HT29, and SW480) carrying wtPTEN than in normal colon fibroblast cells (CCD-18Co) carrying wtPTEN. This suppression was induced through downregulation of the Akt/PKB pathway, dephosphorylation of focal adhesion kinase (FAK) and mitogen-activated protein kinase (MAPK) and cell-cycle arrest at the G2/M phase, but not the G1 phase. Furthermore, treatment of human colorectal tumor xenografts (HT-29, and SW480) with Ad-PTEN resulted in significant (P=0.01) suppression of tumor growth. These results indicate that Ad-PTEN exerts its tumor-suppressive effect on colorectal cancer cells through inhibition of cell-cycle progression and induction of cell death. Thus Ad-PTEN may be a potential therapeutic for treatment of colorectal cancers.


Subject(s)
Adenoviridae/genetics , Colorectal Neoplasms/therapy , Genetic Therapy/methods , Genetic Vectors/administration & dosage , Phosphoric Monoester Hydrolases/genetics , Protein Serine-Threonine Kinases , Tumor Suppressor Proteins/genetics , Animals , Apoptosis/genetics , Blotting, Western/methods , Caspases/metabolism , Cell Cycle/genetics , Cell Division/genetics , Colorectal Neoplasms/metabolism , Colorectal Neoplasms/pathology , DNA-Binding Proteins/genetics , Enzyme Activation , Forkhead Box Protein O1 , Forkhead Transcription Factors , Gene Expression , Genetic Vectors/genetics , Glycogen Synthase Kinase 3/genetics , Humans , Mice , Mice, Nude , Neoplasm Transplantation , PTEN Phosphohydrolase , Proto-Oncogene Proteins/genetics , Proto-Oncogene Proteins c-akt , Transcription Factors/genetics , Transplantation, Heterologous
6.
Bioorg Med Chem Lett ; 11(5): 685-8, 2001 Mar 12.
Article in English | MEDLINE | ID: mdl-11266169

ABSTRACT

Starting from the tetrahydroisoquinoline SB-277011 1, a novel series of 5-substituted-2,3-dihydro-1H-isoindoles has been designed. Subsequent optimisation resulted in identification of 19, which has high affinity for the dopamine D3 receptor (pKi 8.3) and > or = 100-fold selectivity over other aminergic receptors. In rat studies 19 was brain penetrant with an excellent pharmacokinetic profile (oral bioavailability 77%, t1/2 5.2h).


Subject(s)
Dopamine Antagonists/chemistry , Dopamine Antagonists/pharmacology , Indoles/chemistry , Indoles/pharmacology , Receptors, Dopamine D2/metabolism , Animals , Brain/metabolism , CHO Cells , Cricetinae , Dopamine Antagonists/chemical synthesis , Dopamine Antagonists/metabolism , Drug Design , Humans , Indoles/chemical synthesis , Indoles/metabolism , Models, Molecular , Molecular Structure , Radioligand Assay , Rats , Receptors, Dopamine D3
7.
Am J Respir Crit Care Med ; 163(3 Pt 1): 658-64, 2001 Mar.
Article in English | MEDLINE | ID: mdl-11254520

ABSTRACT

A respiratory therapist-driven weaning protocol incorporating daily screens, spontaneous breathing trials (SBT), and prompts to caregivers has been associated with superior outcomes in mechanically ventilated medical patients. To determine the effectiveness of this approach in neurosurgical (NSY) patients, we conducted a randomized controlled trial involving 100 patients over a 14-mo period. All had daily screens of weaning parameters. If these were passed, a 2-h SBT was performed in the Intervention group. Study physicians communicated positive SBT results, and the decision to extubate was made by the primary NSY team. Patients in the Intervention (n = 49) and Control (n = 51) groups had similar demographic characteristics, illness severity, and neurologic injuries. Among all patients, 87 (45 in the Control and 42 in the Intervention group) passed at least one daily screen. Forty (82%) patients in the Intervention group passed SBT, but a median of 2 d passed before attempted extubation, primarily because of concerns about the patient's sensorium (84%). Of 167 successful SBT, 126 (75%) did not lead to attempted extubation on the same day. The median time of mechanical ventilation was 6 d in both study groups, and there were no differences in outcomes. Overall complications included death (36%), reintubation (16%), and pneumonia (9%). Tracheostomies were created in 29% of patients. Multivariate analysis showed that Glasgow Coma Scale (GCS) score (p < 0.0001) and partial pressure of arterial oxygen/fraction of inspired oxygen ratio (p < 0.0001) were associated with extubation success. The odds of successful extubation increased by 39% with each GCS score increment. A GCS score > or = 8 at extubation was associated with success in 75% of cases, versus 33% for a GCS score < 8 (p < 0.0001). Implementation of a weaning protocol based on traditional respiratory physiologic parameters had practical limitations in NSY patients, owing to concerns about neurologic impairment. Whether protocols combining respiratory parameters with neurologic measures lead to superior outcomes in this population requires further investigation.


Subject(s)
Nervous System Diseases/surgery , Postoperative Care , Ventilator Weaning , Adolescent , Adult , Aged , Aged, 80 and over , Female , Humans , Male , Middle Aged , Treatment Outcome
8.
Mol Ther ; 3(3): 337-50, 2001 Mar.
Article in English | MEDLINE | ID: mdl-11273776

ABSTRACT

Delivery of therapeutic genes to disseminated tumor sites has been a major challenge in the field of cancer gene therapy due to lack of an efficient vector delivery system. Among the various vectors currently available, liposomes have shown promise for the systemic delivery of genes to distant sites with minimal toxicity. In this report, we describe an improved extruded DOTAP:cholesterol (DOTAP:Chol) cationic liposome that efficiently delivers therapeutic tumor suppressor genes p53 and FHIT, which are frequently altered in lung cancer, to localized human primary lung cancers and to experimental disseminated metastases. Transgene expression was observed in 25% of tumor cells per tumor in primary tumors and 10% in disseminated tumors. When treated with DOTAP:Chol-p53 and -FHIT complex, significant suppression was observed in both primary (P < 0.02) and metastatic lung tumor growth (P < 0.007). Furthermore, repeated multiple treatments revealed a 2.5-fold increase in gene expression and increased therapeutic efficacy compared to single treatment. Finally, animal survival experiments revealed prolonged survival (median survival time: 76 days, P < 0.001 for H1299; and 96 days, P = 0.04 for A549) when treated with liposome-p53 DNA complex. Our findings may be of importance in the development of treatments for primary and disseminated human lung cancers.


Subject(s)
Acid Anhydride Hydrolases , Genes, Tumor Suppressor , Genes, p53/genetics , Genetic Therapy , Liposomes , Lung Neoplasms/therapy , Neoplasm Proteins , Proteins/genetics , Animals , Fatty Acids, Monounsaturated , Female , Gene Expression , Genes, p53/drug effects , Humans , Lung Neoplasms/genetics , Mice , Mice, Nude , Neoplasm Metastasis , Proteins/drug effects , Proteins/therapeutic use , Quaternary Ammonium Compounds , Time Factors , Transgenes , Transplantation, Heterologous , Tumor Cells, Cultured
9.
Gut ; 48(3): 304-9, 2001 Mar.
Article in English | MEDLINE | ID: mdl-11171817

ABSTRACT

BACKGROUND: The incidence of oesophageal adenocarcinoma has increased greatly. Barrett's oesophagus is a known risk factor. AIMS: To identify changes in the incidence, prevalence, and outcome of Barrett's oesophagus in a defined population. SUBJECTS: Residents of Olmsted County, Minnesota, with clinically diagnosed Barrett's oesophagus, or oesophageal or oesophagogastric junction adenocarcinoma. METHODS: Cases were identified using the Rochester Epidemiology Project medical records linkage system. Records were reviewed with follow up to 1 January 1998. RESULTS: The incidence of clinically diagnosed Barrett's oesophagus (>3 cm) increased 28-fold from 0.37/100 000 person years in 1965-69 to 10.5/100 000 in 1995-97. Of note, gastroscopic examinations increased 22-fold in this same time period. The prevalence of diagnosed Barrett's oesophagus increased from 22.6 (95% confidence interval (CI) 11.7-33.6) per 100 000 in 1987 to 82.6/100 000 in 1998. The prevalence of short segment Barrett's oesophagus (<3 cm) in 1998 was 33.4/ 100 000. Patients with Barrett's oesophagus had shorter than expected survival but only one patient with Barrett's oesophagus died from adenocarcinoma. Only four of 64 adenocarcinomas occurred in patients with previously known Barrett's oesophagus. CONCLUSIONS: The incidence and prevalence of clinically diagnosed Barrett's oesophagus have increased in parallel with the increased use of endoscopy. We infer that the true population prevalence of Barrett's oesophagus has not changed greatly, although the incidence of oesophageal adenocarcinoma increased 10-fold. Many adenocarcinomas occurred in patients without a previous diagnosis of Barrett's oesophagus, suggesting that many people with this condition remain undiagnosed in the community.


Subject(s)
Adenocarcinoma/epidemiology , Barrett Esophagus/epidemiology , Esophageal Neoplasms/epidemiology , Adenocarcinoma/etiology , Aged , Barrett Esophagus/complications , Confidence Intervals , Esophageal Neoplasms/etiology , Female , Humans , Incidence , Male , Medical Record Linkage , Middle Aged , Minnesota/epidemiology , Poisson Distribution , Prevalence , Prognosis , Risk Factors , Survival Analysis
10.
J Magn Reson Imaging ; 13(2): 207-14, 2001 Feb.
Article in English | MEDLINE | ID: mdl-11169826

ABSTRACT

This study investigates the impact of imaging coil length and consequent truncation of the arterial input function on the perfusion signal contrast obtained in the flow-sensitive alternating inversion recovery (FAIR) perfusion imaging measurement. We examined the difference in perfusion contrast achieved with head, head and neck, and body imaging coils based on the hypothesis that the standard head coil provides a truncated input function compared with that provided by the body coil and that this effect will be accentuated at long inversion times. The TI-dependent cerebral response of the FAIR sequence was examined at 1.5 T by varying the TI from 200 to 3500 msec with both the head and whole body coils (n = 5) as well as using a head and neck coil (n = 3). Difference signal intensity DeltaM and quantitative cerebral blood flow (CBF) were plotted against TI for each coil configuration. Despite a lower signal-to-noise ratio, relative CBF was significantly greater when measured with the body or head and neck coil compared with the standard head coil for longer inversion times (two-way ANOVA, P < or = 0.002). This effect is attributed to truncation of the arterial input function of labeled water by the standard head coil and the resultant inflow of unlabeled spins to the image slice during control image acquisition, resulting in overestimation of CBF. The results support the conclusion that the arterial input function depends on the anatomic extent of the inversion pulse in FAIR, particularly at longer mixing times (TI > 1200 msec at 1.5 T). Use of a head and neck coil ensures adequate inversion while preserving SNR that is lost in the body coil.


Subject(s)
Brain Ischemia/diagnosis , Brain/blood supply , Image Enhancement/instrumentation , Image Processing, Computer-Assisted/instrumentation , Magnetic Resonance Imaging/instrumentation , Adult , Blood Flow Velocity/physiology , Brain Ischemia/physiopathology , Equipment Design , Humans , Infant, Newborn , Male , Reference Values , Regional Blood Flow/physiology , Sensitivity and Specificity
11.
J Genet Psychol ; 162(4): 412-29, 2001 Dec.
Article in English | MEDLINE | ID: mdl-11831351

ABSTRACT

This study addressed how adolescents come to develop a sense of ethnic identity. The author examined ethnic identity development as a process that occurs simultaneously with the development of ego identity and attitudes toward groups other than one's own. A multiethnic sample of 297 adolescents and young adults (aged 13 to 26 years) completed the Extended Objective Measure of Ego Identity Scale Revision 2 (EOMEIS2; L. Bennion & G. Adams, 1986), the Multigroup Ethnic Identity Measure (MEIM; J. Phinney, 1992), and the Other Group Orientation Scale (J. Phinney, 1992). An Age x Ethnic Group x Gender experimental design was used to determine whether these factors contributed differently to ethnic identity and ego identity. Analyses showed significant differences in the level of ethnic identity development among the ethnic groups. More pronounced age differences were found at the lower levels of ego identity development than at the more advanced levels.


Subject(s)
Ego , Ethnicity , Self Concept , Social Identification , Adolescent , Adult , Female , Humans , Male , Psychology, Adolescent , Surveys and Questionnaires
12.
Bioorg Med Chem Lett ; 10(22): 2553-5, 2000 Nov 20.
Article in English | MEDLINE | ID: mdl-11086728

ABSTRACT

Starting from the dopamine D3 receptor antagonist SB-277011 1, a series of 2,3,4,5-tetrahydro-1H-3-benzazepines has been identified with high affinity for the dopamine D3 receptor and selectivity over the D2 receptor. The 3-acetamido-2-fluorocinnamide derivative 20 gave high D3 receptor affinity (pKi 8.4) with 130-fold selectivity over the 2, receptor.


Subject(s)
Nitriles/pharmacology , Quinolines/pharmacology , Receptors, Dopamine D2/drug effects , Tetrahydroisoquinolines , Animals , Nitriles/chemistry , Quinolines/chemistry , Rats , Receptors, Dopamine D3
13.
J Pharmacol Exp Ther ; 294(3): 1154-65, 2000 Sep.
Article in English | MEDLINE | ID: mdl-10945872

ABSTRACT

SB-277011-A (trans-N-[4-[2-(6-cyano-1,2,3, 4-tetrahydroisoquinolin-2-yl)ethyl]cyclohexyl]-4-quinolininecarboxamide), is a brain-penetrant, high-affinity, and selective dopamine D(3) receptor antagonist. Radioligand-binding experiments in Chinese hamster ovary (CHO) cells transfected with human dopamine D(3) or D(2 long) (hD(3), hD(2)) receptors showed SB-277011-A to have high affinity for the hD(3) receptor (pK(i) = 7.95) with 100-fold selectivity over the hD(2) receptor and over 66 other receptors, enzymes, and ion channels. Similar radioligand-binding data for SB-277011-A were obtained from CHO cells transfected with rat dopamine D(3) or D(2). In the microphysiometer functional assay, SB-277011-A antagonized quinpirole-induced increases in acidification in CHO cells overexpressing the hD(3) receptor (pK(b) = 8.3) and was 80-fold selective over hD(2) receptors. Central nervous system penetration studies showed that SB-277011-A readily entered the brain. In in vivo microdialysis studies, SB-277011-A (2. 8 mg/kg p.o.) reversed the quinelorane-induced reduction of dopamine efflux in the nucleus accumbens but not striatum, a regional selectivity consistent with the distribution of the dopamine D(3) receptor in rat brain. SB-277011-A (2-42.3 mg/kg p.o.) did not affect spontaneous locomotion, or stimulant-induced hyperlocomotion. SB-277011-A (4.1-42.2 mg/kg p.o.) did not reverse prepulse inhibition deficits in apomorphine- or quinpirole-treated rats, but did significantly reverse the prepulse inhibition deficit in isolation-reared rats at a dose of 3 mg/kg p.o. SB-277011-A (2.5-78. 8 mg/kg p.o.) was noncataleptogenic and did not raise plasma prolactin levels. Thus, dopamine D(3) receptor blockade produces few of the behavioral effects characteristic of nonselective dopamine receptor antagonists. The effect of SB-277011-A on isolation-induced prepulse inhibition deficit suggests that blockade of dopamine D(3) receptors may benefit the treatment of schizophrenia.


Subject(s)
Dopamine Antagonists/pharmacology , Nitriles/pharmacology , Quinolines/pharmacology , Receptors, Dopamine D2/drug effects , Tetrahydroisoquinolines , Animals , Brain/metabolism , CHO Cells , Catalepsy/chemically induced , Cricetinae , Dopamine Antagonists/metabolism , Dopamine Antagonists/toxicity , Humans , Male , Microdialysis , Motor Activity/drug effects , Nitriles/metabolism , Nitriles/toxicity , Prolactin/blood , Quinolines/metabolism , Quinolines/toxicity , Radioligand Assay , Rats , Rats, Inbred Strains , Rats, Sprague-Dawley , Receptors, Dopamine D2/metabolism , Receptors, Dopamine D3 , Reflex, Startle/drug effects , Reverse Transcriptase Polymerase Chain Reaction , Transfection
14.
J Trauma ; 48(6): 1081-90, 2000 Jun.
Article in English | MEDLINE | ID: mdl-10866255

ABSTRACT

BACKGROUND: Administration of anti-CD11B, a monoclonal antibody directed against the leukocyte adhesion molecule CD11B, results in decreased neutrophil infiltration into injured tissue after experimental ischemia. We determined the effect of anti-CD11B administration on neutrophil migration and neurologic functioning after experimental cortical trauma. METHODS: Injuries were produced by a pneumatic impactor. Treatment animals received anti-CD11B after injury. Neurologic functioning was quantitated at 1, 12, and 24 hours after injury. Neutrophil migration was assessed with the myeloperoxidase assay. RESULTS: Neutrophil influx was increased in injured cortex after trauma. Anti-CD11B significantly reduced neutrophil influx. There was no significant improvement in neurologic functioning after MAb administration. CONCLUSIONS: These results show there is marked neutrophil response to injury as produced with the pneumatic contusion model. This migration may be significantly attenuated by administration of a anti-CD11B.


Subject(s)
Antibodies, Monoclonal/therapeutic use , Brain Injuries/drug therapy , Cell Migration Inhibition , E-Selectin/drug effects , Inflammation/drug therapy , Neutrophils/drug effects , Analysis of Variance , Animals , Antibodies, Monoclonal/pharmacology , Brain Injuries/immunology , Male , Motor Activity/drug effects , Neurologic Examination , Neutrophils/physiology , Rats , Rats, Sprague-Dawley
15.
J Med Chem ; 43(9): 1878-85, 2000 May 04.
Article in English | MEDLINE | ID: mdl-10794704

ABSTRACT

A selective dopamine D(3) receptor antagonist offers the potential for an effective antipsychotic therapy, free of the serious side effects of currently available drugs. Using clearance and brain penetration studies as a screen, a series of 1,2,3, 4-tetrahydroisoquinolines, exemplified by 13, was identified with high D(3) affinity and selectivity against the D(2) receptor. Following examination of molecular models, the flexible butyl linker present in 13 was replaced by a more conformationally constrained cyclohexylethyl linker, leading to compounds with improved oral bioavailability and selectivity over other receptors. Subsequent optimization of this new series to improve the cytochrome P450 inhibitory profile and CNS penetration gave trans-N-[4-[2-(6-cyano-1, 2,3, 4-tetrahydroisoquinolin-2-yl)ethyl]cyclohexyl]-4-quinolinecarbo xamide (24, SB-277011). This compound is a potent and selective dopamine D(3) receptor antagonist with high oral bioavailability and brain penetration in the rat and represents an excellent new chemical tool for the investigation of the role of the dopamine D(3) receptor in the CNS.


Subject(s)
Central Nervous System/metabolism , Dopamine Antagonists/chemical synthesis , Nitriles/chemical synthesis , Quinolines/chemical synthesis , Receptors, Dopamine D2/drug effects , Tetrahydroisoquinolines , Animals , Biological Availability , Brain/drug effects , Brain/metabolism , CHO Cells , Catalepsy/chemically induced , Catalepsy/psychology , Central Nervous System/drug effects , Cricetinae , Dopamine Antagonists/pharmacokinetics , Dopamine Antagonists/pharmacology , Half-Life , Humans , Male , Microdialysis , Nitriles/pharmacokinetics , Nitriles/pharmacology , Prolactin/blood , Quinolines/pharmacokinetics , Quinolines/pharmacology , Radioligand Assay , Rats , Rats, Sprague-Dawley , Receptors, Dopamine D3
16.
Gene Ther ; 7(23): 2051-7, 2000 Dec.
Article in English | MEDLINE | ID: mdl-11175318

ABSTRACT

The melanoma differentiation-associated gene-7 (mda-7), cloned from a human melanoma cell line H0-1, is known to induce tumor cell-selective growth inhibition in breast cancer cells in vitro and loss of tumorigenicity ex vivo. Yet, the mechanisms underlying these effects are still unknown. Therefore, we investigated these mechanisms on the molecular level in human non-small cell lung carcinoma (NSCLC) cells in vitro. Overexpression of mda-7 protein by Ad-mda-7 significantly suppressed proliferation and induced G2/M cell cycle arrest in wild-type p53 (A549, H460), and p53-null (H1299) non-small cell lung cancer cell lines, but not in normal human lung fibroblast (NHLF) cells. p53, Bax, and Bak protein expression was up-regulated in wild-type p53 tumor cell lines, but not in p53-null cells, suggesting that an intact p53 pathway was required for Bax and Bak induction. However, in all three cancer cell lines tested, activation of the caspase cascade and cleavage of poly(ADP-ribose) polymerase (PARP) appeared to be independent of the p53 mutational status. Together, these results suggest that apoptosis may be induced via multiple pathways by Ad-mda-7 in lung cancer cells and that Ad-mda-7 has the potential to become a novel therapeutic for clinical cancer gene therapy. Gene Therapy (2000) 7, 2051-2057.


Subject(s)
Carcinoma, Non-Small-Cell Lung/therapy , Genes, Tumor Suppressor , Genetic Therapy/methods , Growth Substances/genetics , Interleukins , Lung Neoplasms/therapy , Proto-Oncogene Proteins c-bcl-2 , Adenoviridae/genetics , Apoptosis/genetics , Blotting, Western/methods , Caspases/metabolism , Cell Cycle , Cell Differentiation , Gene Expression Regulation , Genes, p53 , Genetic Vectors/administration & dosage , Growth Substances/analysis , Humans , Immunohistochemistry/methods , Membrane Proteins/genetics , Proto-Oncogene Proteins/genetics , Transfection , Tumor Cells, Cultured , bcl-2 Homologous Antagonist-Killer Protein , bcl-2-Associated X Protein
18.
J Magn Reson Imaging ; 9(6): 761-7, 1999 Jun.
Article in English | MEDLINE | ID: mdl-10373023

ABSTRACT

Pulsed arterial spin labeling magnetic resonance techniques have been developed recently to estimate cerebral blood flow (CBF). Flow-sensitive alternating inversion recovery (FAIR) is one such technique that has been implemented successfully in humans. Un-inverted FAIR (UNFAIR) is an alternative technique in which the flow-sensitive image is acquired following inversion of all spins outside the slice of interest, and the control image is acquired without any spin labeling. This approach is potentially more efficient than FAIR since the UNFAIR control image is entirely flow independent and need only be acquired once. Here, we describe implementation of the sequence on a clinical 1.5 T magnetic resonance system. Both FAIR and UNFAIR perfusion-weighted images were obtained from six normal volunteers. Wash-in/wash-out curves measured in cortical gray and white matter were practically identical for the two techniques, as predicted by our model.


Subject(s)
Brain/blood supply , Magnetic Resonance Angiography/methods , Adult , Blood Flow Velocity , Cerebrovascular Circulation , Female , Humans , Image Processing, Computer-Assisted/methods , Male
19.
NMR Biomed ; 12(1): 15-25, 1999 Feb.
Article in English | MEDLINE | ID: mdl-10195325

ABSTRACT

A new approach is presented for rapid and continuous monitoring of cerebral perfusion which is based upon line-scan MR column imaging with arterial spin tagging (AST) of endogenous water. Spin tagging of arterial water protons is accomplished using adiabatic fast passage inversion, followed by acquisition of the perfusion sensitive MR signal from a column placed at the desired level through the brain using line scan localization techniques. A perfusion sensitive line scan is followed by a non-perfusion sensitive line scan, and perfusion is calculated pixel-by-pixel from the intensity difference of the two lines. Continuous perfusion measurements are reported with temporal resolution of 10 s in pixels of volume 0.027 cm3 or less. Examples of the methodology are given during hypercapnic challenge induced with carbon dioxide, and during an ischemic event induced by reversible middle cerebral artery occlusion. The method is also used to characterize the signal response as a function of arterial inversion time and post inversion acquisition delay. These methods permit rapid and continuous monitoring of cerebral perfusion with high spatial resolution, and can be interleaved with MR measurements of diffusion and T1 to follow the progression of cerebral events during physiological or pharmacological intervention.


Subject(s)
Brain/blood supply , Cerebrovascular Circulation/physiology , Nuclear Magnetic Resonance, Biomolecular/methods , Animals , Monitoring, Physiologic/methods , Perfusion , Rats
20.
Bioorg Med Chem Lett ; 9(2): 179-84, 1999 Jan 18.
Article in English | MEDLINE | ID: mdl-10021923

ABSTRACT

Using clearance and brain penetration studies as a screen, tetrahydroisoquinoline 3 was identified as a lead having low clearance in rats (CLb 20 ml/min/kg). Introduction of a 7-CF3SO2O- substituent into the tetrahydroisoquinoline, followed by replacement of the biphenylamido group of 3 by a 3-indolylpropenamido group gave 31, having high D3 receptor affinity (pKi 8.4) and 150 fold selectivity over the D2 receptor.


Subject(s)
Isoquinolines/chemical synthesis , Isoquinolines/pharmacology , Receptors, Dopamine D2/chemistry , Animals , Brain/drug effects , Isoquinolines/administration & dosage , Isoquinolines/blood , Models, Molecular , Rats , Receptors, Dopamine D3
SELECTION OF CITATIONS
SEARCH DETAIL
...